Selective Raf inhibition in cancer therapy
暂无分享,去创建一个
Erica A Golemis | Ilya G Serebriiskii | Vladimir Khazak | E. Golemis | V. Khazak | I. Astsaturov | I. Serebriiskii | Igor Astsaturov
[1] D. Barford,et al. Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF , 2004, Cell.
[2] M. Moasser. Targeting the function of the HER2 oncogene in human cancer therapeutics , 2007, Oncogene.
[3] P. Shannon,et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. , 2003, Genome research.
[4] G. Reifenberger,et al. Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas , 2004, Acta Neuropathologica.
[5] T. Papadopoulos,et al. Lung-targeted expression of the c-Raf-1 kinase in transgenic mice exposes a novel oncogenic character of the wild-type protein. , 2000, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[6] Prakash Chinnaiyan,et al. Dual-Agent Molecular Targeting of the Epidermal Growth Factor Receptor (EGFR) , 2004, Cancer Research.
[7] R. Salgia,et al. Epidermal Growth Factor Receptor–Mediated Signal Transduction in the Development and Therapy of Gliomas , 2006, Clinical Cancer Research.
[8] J. Fueller,et al. RAF kinases and mitochondria. , 2007, Biochimica et biophysica acta.
[9] S. Dedhar,et al. Combined inhibition of the phosphatidylinositol 3-kinase/Akt and Ras/mitogen-activated protein kinase pathways results in synergistic effects in glioblastoma cells , 2006, Molecular Cancer Therapeutics.
[10] L. Neckers,et al. Heat shock protein 90: The cancer chaperone , 2007, Journal of Biosciences.
[11] G. Gores,et al. The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006 , 2005, Oncogene.
[12] David A. Cheresh,et al. Differential αv integrin–mediated Ras-ERK signaling during two pathways of angiogenesis , 2003, The Journal of cell biology.
[13] W. Rathmell,et al. Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] P. O'dwyer,et al. Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A). , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] K. N. Chandrika,et al. Analysis of the human protein interactome and comparison with yeast, worm and fly interaction datasets , 2006, Nature Genetics.
[16] Richard Marais,et al. The RAF proteins take centre stage , 2004, Nature Reviews Molecular Cell Biology.
[17] S. Wilhelm,et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. , 2006, Cancer research.
[18] Apurva A Desai,et al. Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.
[19] P. Uetz,et al. The interactome of human EGF/ErbB receptors , 2006, Molecular systems biology.
[20] M. Vieth,et al. Mutations of BRAF and KRAS2 in the development of Barrett's adenocarcinoma , 2004, Oncogene.
[21] U. Gatzemeier,et al. Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] Yuri E Nikiforov,et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. , 2003, Cancer research.
[23] M. Barbacid,et al. RAS oncogenes: the first 30 years , 2003, Nature Reviews Cancer.
[24] H. Varmus,et al. KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib , 2005, PLoS medicine.
[25] M. Marra,et al. EGF activates an inducible survival response via the RAS-> Erk-1/2 pathway to counteract interferon-α-mediated apoptosis in epidermoid cancer cells , 2003, Cell Death and Differentiation.
[26] G. Bollag,et al. Discovery of a novel Raf kinase inhibitor. , 2001, Endocrine-related cancer.
[27] S. Schreiber,et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[28] M. Ratain,et al. Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis , 2006, British Journal of Cancer.
[29] J. D. de Bono,et al. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu). , 2007, European journal of cancer.
[30] A. Lièvre,et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. , 2006, Cancer research.
[31] M. Mann,et al. Phosphotyrosine interactome of the ErbB-receptor kinase family , 2005, Molecular systems biology.
[32] E. Eisenhauer,et al. Phase II study of CGP 69846A (ISIS 5132) in recurrent epithelial ovarian cancer: an NCIC clinical trials group study (NCIC IND.116). , 2003, Gynecologic oncology.
[33] V. Soldatenkov,et al. Inhibition of Raf-1 protein kinase by antisense phosphorothioate oligodeoxyribonucleotide is associated with sensitization of human laryngeal squamous carcinoma cells to gamma radiation. , 1997, The cancer journal from Scientific American.
[34] E. Wang,et al. C-Raf antagonizes apoptosis induced by IFN-α in human lung cancer cells by phosphorylation and increase of the intracellular content of elongation factor 1A , 2007, Cell Death and Differentiation.
[35] D. Aust,et al. Mutations of the BRAF gene in ulcerative colitis-related colorectal carcinoma. , 2004, International journal of cancer.
[36] Jeffrey W. Clark,et al. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. , 2007, The oncologist.
[37] D. Amadori,et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] Sean R. Eddy,et al. Total Information Awareness for Worm Genetics , 2006, Science.
[39] Wei Li,et al. VEGF prevents apoptosis of human microvascular endothelial cells via opposing effects on MAPK/ERK and SAPK/JNK signaling. , 1999, Experimental cell research.
[40] P. Jeffrey,et al. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. , 2005, Cancer cell.
[41] Oliver E. Sturm,et al. Computational modelling of the receptor-tyrosine-kinase-activated MAPK pathway. , 2005, The Biochemical journal.
[42] Minoru Yoshida,et al. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. , 2005, Molecular cell.
[43] I. Berberich,et al. Activation of the MAP kinase pathway induces apoptosis in the Merkel cell carcinoma cell line UISO. , 2007, The Journal of investigative dermatology.
[44] S. H. Lee,et al. BRAF mutations in acute leukemias , 2004, Leukemia.
[45] C. Tangen,et al. Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] J. Lundeberg,et al. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing , 2006, Melanoma research.
[47] S. Wilhelm,et al. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models , 2007, Cancer Chemotherapy and Pharmacology.
[48] Philip R. Cohen,et al. Paradoxical activation of Raf by a novel Raf inhibitor. , 1999, Chemistry & biology.
[49] Rakesh Kumar,et al. Commentary: targeting colorectal cancer through molecular biology. , 2005, Seminars in oncology.
[50] M. Santoro,et al. BAY 43-9006 inhibition of oncogenic RET mutants. , 2006, Journal of the National Cancer Institute.
[51] M. Beeram,et al. Raf: a strategic target for therapeutic development against cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[52] P. O'dwyer,et al. c-raf-1 depletion and tumor responses in patients treated with the c-raf-1 antisense oligodeoxynucleotide ISIS 5132 (CGP 69846A). , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[53] P. Atadja,et al. Selective Growth Inhibition of Tumor Cells by a Novel Histone Deacetylase Inhibitor, NVP-LAQ824 , 2004, Cancer Research.
[54] T. Pawson,et al. Mutational activation of c-raf-1 and definition of the minimal transforming sequence , 1990, Molecular and cellular biology.
[55] M. DePamphilis,et al. HUMAN DISEASE , 1957, The Ulster Medical Journal.
[56] Y. Yamanaka. The immunohistochemical expressions of epidermal growth factors, epidermal growth factor receptors and c-erbB-2 oncoprotein in human pancreatic cancer. , 1992, Nihon Ika Daigaku zasshi.
[57] F. Sommerer,et al. Mutations of the BRAF gene in squamous cell carcinoma of the head and neck , 2003, Oncogene.
[58] Todd R. Golub,et al. BRAF mutation predicts sensitivity to MEK inhibition , 2006, Nature.
[59] A. J. Mixson,et al. Small interfering RNA targeting Raf-1 inhibits tumor growth in vitro and in vivo , 2005, Cancer Gene Therapy.
[60] Weiwei Zhong,et al. Genome-Wide Prediction of C. elegans Genetic Interactions , 2006, Science.
[61] T. Barrette,et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. , 2007, Neoplasia.
[62] D. Fabbro,et al. Antitumor activity of a C-raf antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted subcutaneously into nude mice. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[63] D. Christiansen,et al. Mutations of genes in the receptor tyrosine kinase (RTK)/RAS-BRAF signal transduction pathway in therapy-related myelodysplasia and acute myeloid leukemia , 2005, Leukemia.
[64] F. Sarkar,et al. A phase II trial of 17-allylamino-17- demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. , 2005, Clinical prostate cancer.
[65] M. Nikiforova,et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. , 2003, The Journal of clinical endocrinology and metabolism.
[66] A. Kolbus,et al. ERK and Beyond: Insights from B-Raf and Raf-1 Conditional Knockouts , 2006, Cell cycle.
[67] Yingchun Lu,et al. Solution phase parallel synthesis and evaluation of MAPK inhibitory activities of close structural analogues of a Ras pathway modulator. , 2004, Bioorganic & medicinal chemistry letters.
[68] C. Rudin,et al. Phase I study of liposome-encapsulated c-raf antisense oligodeoxyribonucleotide infusion in combination with radiation therapy in patients with advanced malignancies. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.
[69] D. Tuveson,et al. Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. , 2005, Cancer research.
[70] D. Barford,et al. Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. , 2005, Molecular cell.
[71] R. Figlin,et al. The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial in North America: Safety and efficacy , 2007 .
[72] Chunlei Zhang,et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). , 2007, Blood.
[73] H. Inoue,et al. Amplification of Both c‐myc and c‐raf‐1 Oncogenes in a Human Osteosarcoma , 1989, Japanese journal of cancer research : Gann.
[74] R. Maki,et al. Clinical results of a phase II study of sorafenib in patients (pts) with non-GIST sarcomas (CTEP study #7060) , 2007 .
[75] John Calvin Reed,et al. Bcl-2 interacting protein, BAG-1, binds to and activates the kinase Raf-1. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[76] J. McCubrey,et al. BAY-43-9006 Bayer/Onyx. , 2003, Current opinion in investigational drugs.
[77] H. Mott,et al. The solution structure of the Raf-1 cysteine-rich domain: a novel ras and phospholipid binding site. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[78] A. Barabasi,et al. The human disease network , 2007, Proceedings of the National Academy of Sciences.
[79] Walter Kolch,et al. Role of the Kinase MST2 in Suppression of Apoptosis by the Proto-Oncogene Product Raf-1 , 2004, Science.
[80] D. Fraker,et al. Sorafenib targets BRAF and VEGFR in metastatic thyroid carcinoma , 2007 .
[81] C. J. Barnes,et al. Insulin-like Growth Factor Receptor as a Therapeutic Target in Head and Neck Cancer , 2007, Clinical Cancer Research.
[82] S. Mahooti,et al. Distinct signal transduction pathways are utilized during the tube formation and survival phases of in vitro angiogenesis. , 1998, Journal of cell science.
[83] F. Sommerer,et al. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma , 2003, Gut.
[84] J. V. Van Gompel,et al. ZM336372, a Raf-1 activator, suppresses growth and neuroendocrine hormone levels in carcinoid tumor cells , 2005, Molecular Cancer Therapeutics.
[85] D. Beach,et al. Raf1 interaction with Cdc25 phosphatase ties mitogenic signal transduction to cell cycle activation. , 1995, Genes & development.
[86] E. Mekada,et al. Involvement of deregulated epiregulin expression in tumorigenesis in vivo through activated Ki-Ras signaling pathway in human colon cancer cells. , 2000, Cancer research.
[87] W. Kolch. Coordinating ERK/MAPK signalling through scaffolds and inhibitors , 2005, Nature Reviews Molecular Cell Biology.
[88] A. Ferrer,et al. RAF-1 over-expression does condition survival of patients affected by aggressive mantle cell lymphoma. , 2007, Leukemia research.
[89] J. Fagin,et al. Inhibitors of Raf Kinase Activity Block Growth of Thyroid Cancer Cells with RET/PTC or BRAF Mutations In vitro and In vivo , 2006, Clinical Cancer Research.
[90] P. Harari,et al. Targeting epidermal growth factor receptor signaling in the treatment of head and neck cancer , 2006, Expert review of anticancer therapy.
[91] M. Shipitsin,et al. Activation of RalA is critical for Ras-induced tumorigenesis of human cells. , 2005, Cancer cell.
[92] S. Ramurthy,et al. CHIR-265 is a potent selective inhibitor of c-Raf/B-Raf/mutB-Raf that effectively inhibits proliferation and survival of cancer cell lines with Ras/Raf pathway mutations , 2006 .
[93] U. Kasid,et al. Nucleotide sequence analysis of c‐raf‐1 cDNA and promoter from a radiation‐resistant human squamous carcinoma cell line: Deletion within exon 17 , 1993, Molecular carcinogenesis.
[94] M. Garnett,et al. Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF. , 2005, Cancer research.
[95] Paul Workman,et al. Drugging the Cancer Chaperone HSP90 , 2007, Annals of the New York Academy of Sciences.
[96] P. Dent,et al. Apoptosis Induced by the Kinase Inhibitor BAY 43-9006 in Human Leukemia Cells Involves Down-regulation of Mcl-1 through Inhibition of Translation* , 2005, Journal of Biological Chemistry.
[97] U. Rapp,et al. Raf kinases: Oncogenesis and drug discovery , 2006, International journal of cancer.
[98] Jie Zhang,et al. Inhibitors of Ras/Raf-1 interaction identified by two-hybrid screening revert Ras-dependent transformation phenotypes in human cancer cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[99] M. Schimek,et al. Two transforming C-RAF germ-line mutations identified in patients with therapy-related acute myeloid leukemia. , 2006, Cancer research.
[100] Manuel Hidalgo,et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[101] G. Tzivion,et al. Raf kinases: function, regulation and role in human cancer. , 2007, Biochimica et biophysica acta.
[102] A. Dritschilo,et al. Enhanced therapeutic effects of doxorubicin and paclitaxel in combination with liposome-entrapped ends-modified raf antisense oligonucleotide against human prostate, lung and breast tumor models. , 2004, International journal of oncology.
[103] Marie Joseph,et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[104] R. Gilbertson,et al. A Phase I Study of 17-Allylaminogeldanamycin in Relapsed/Refractory Pediatric Patients with Solid Tumors: A Children's Oncology Group Study , 2007, Clinical Cancer Research.
[105] R. Britten,et al. Raf-1 kinase activity predicts for paclitaxel resistance in TP53mut, but not TP53wt human ovarian cancer cells. , 2000, Oncology reports.
[106] M. Borner,et al. Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer. A European Organization for Research and Treatment of Cancer (EORTC) Early Clinical Studies Group report. , 2001, European journal of cancer.
[107] K. Flaherty,et al. Mechanisms of hypertension associated with BAY 43-9006. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[108] J. Small,et al. Raf-1 regulates Rho signaling and cell migration , 2005, The Journal of cell biology.
[109] Roded Sharan,et al. PathBLAST: a tool for alignment of protein interaction networks , 2004, Nucleic Acids Res..
[110] A. Nicholson,et al. Mutations of the BRAF gene in human cancer , 2002, Nature.
[111] Daniel A. Haber,et al. Epidermal growth factor receptor mutations in lung cancer , 2007, Nature Reviews Cancer.
[112] M. Stratton,et al. COSMIC 2005 , 2006, British Journal of Cancer.
[113] D. Auclair,et al. BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.
[114] P. Wesseling,et al. RAS/RAF pathway activation in gliomas: the result of copy number gains rather than activating mutations , 2007, Acta Neuropathologica.
[115] S. Adam,et al. Divergent Roles for RalA and RalB in Malignant Growth of Human Pancreatic Carcinoma Cells , 2006, Current Biology.
[116] Pall I. Olason,et al. A human phenome-interactome network of protein complexes implicated in genetic disorders , 2007, Nature Biotechnology.
[117] M. Bednarski,et al. Tumor Regression by Targeted Gene Delivery to the Neovasculature , 2002, Science.
[118] E. Lesnik,et al. Sequence-specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted to human C-raf kinase supports an antisense mechanism of action in vivo. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[119] A. Chinnaiyan,et al. Integrative analysis of the cancer transcriptome , 2005, Nature Genetics.
[120] U. Löhrs,et al. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants. , 2006, Gynecologic oncology.
[121] H. Brauch,et al. Involvement of the RAFI locus, at band 3p25, in the 3p deletion of small‐cell lung cancer , 1991, Genes, chromosomes & cancer.
[122] Richard Wooster,et al. BRAF and RAS mutations in human lung cancer and melanoma. , 2002, Cancer research.
[123] J. Moon,et al. A phase II trial of sorafenib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC): A Southwest Oncology Group (SWOG) trial , 2006 .
[124] A. Dritschilo,et al. RAF antisense oligonucleotide as a tumor radiosensitizer , 2003, Oncogene.
[125] B. Monia,et al. Comparison of strategies targeting Raf‐1 mRNA in ovarian cancer , 2006, International journal of cancer.
[126] K S Thompson,et al. Studies on uptake, sub-cellular trafficking and efflux of antisense oligodeoxynucleotides in glioma cells using self-assembling cationic lipoplexes as delivery systems. , 2000, Journal of drug targeting.
[127] Lori Jardines,et al. Raf-1 protein expression in human breast cancer cells , 2006, Annals of Surgical Oncology.
[128] Jing Chen,et al. Raf-1 promotes cell survival by antagonizing apoptosis signal-regulating kinase 1 through a MEK–ERK independent mechanism , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[129] James Bradner,et al. Inhibition of Histone Deacetylase 6 Acetylates and Disrupts the Chaperone Function of Heat Shock Protein 90 , 2005, Journal of Biological Chemistry.
[130] J. Nemunaitis,et al. A phase I trial of c-Raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[131] O. M. Grbovic,et al. V600E B‐Rafはその安定性にHsp90シャペロンを要求し,Hsp90阻害剤への応答として分解される , 2006 .
[132] P. Cohen,et al. Specificity and mechanism of action of some commonly used protein kinase inhibitors , 2000 .
[133] C. Der,et al. Elucidation of Binding Determinants and Functional Consequences of Ras/Raf-Cysteine-rich Domain Interactions* , 2000, The Journal of Biological Chemistry.
[134] D. Morrison,et al. BCL-2 and BCL-XL Restrict Lineage Choice during Hematopoietic Differentiation* , 2003, Journal of Biological Chemistry.
[135] L. Cantley,et al. Ras, PI(3)K and mTOR signalling controls tumour cell growth , 2006, Nature.
[136] Silvia Benvenuti,et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. , 2005, The Lancet. Oncology.
[137] R. Ramanathan,et al. 17-dimethylaminoethylamino-17-demethoxygeldanamycin in patients with advanced-stage solid tumors and lymphoma: a phase I study. , 2006, Clinical lymphoma & myeloma.
[138] P. Lichter,et al. Gene expression patterns in ependymomas correlate with tumor location, grade, and patient age. , 2003, The American journal of pathology.
[139] M. Marra,et al. The farnesyltransferase inhibitor R115777 (ZARNESTRA®) enhances the pro‐apoptotic activity of interferon‐α through the inhibition of multiple survival pathways , 2007, International journal of cancer.
[140] J. Frost,et al. B-Raf and Raf-1 Are Regulated by Distinct Autoregulatory Mechanisms* , 2005, Journal of Biological Chemistry.
[141] M. Atkins,et al. The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells. , 2006, Cancer research.
[142] R. McLendon,et al. AAL881, a novel small molecule inhibitor of RAF and vascular endothelial growth factor receptor activities, blocks the growth of malignant glioma. , 2006, Cancer research.
[143] D. McMillin,et al. Targeting BRAFV600E in thyroid carcinoma: therapeutic implications , 2007, Molecular Cancer Therapeutics.
[144] A. Bagg,et al. Antisense raf oligodeoxyribonucleotide is a radiosensitizer in vivo. , 1999, Antisense & nucleic acid drug development.
[145] L. Weber,et al. In vitro and in vivo synergy of MCP compounds with mitogen-activated protein kinase pathway– and microtubule-targeting inhibitors , 2007, Molecular Cancer Therapeutics.
[146] R. Nicosia,et al. Regulation of angiogenesis by vascular endothelial growth factor and angiopoietin-1 in the rat aorta model: distinct temporal patterns of intracellular signaling correlate with induction of angiogenic sprouting. , 2002, The American journal of pathology.
[147] S. Keir,et al. The combination of novel low molecular weight inhibitors of RAF (LBT613) and target of rapamycin (RAD001) decreases glioma proliferation and invasion , 2007, Molecular Cancer Therapeutics.
[148] L. Wodicka,et al. A small molecule–kinase interaction map for clinical kinase inhibitors , 2005, Nature Biotechnology.
[149] H. Namba,et al. Clinical implications of pre-operative rapid BRAF analysis for papillary thyroid cancer. , 2007, Endocrine journal.
[150] T. Yao,et al. Regulation of the Dynamics of hsp90 Action on the Glucocorticoid Receptor by Acetylation/Deacetylation of the Chaperone* , 2005, Journal of Biological Chemistry.
[151] E. Eisenhauer,et al. A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[152] J. Charron,et al. Embryonic death of Mek1-deficient mice reveals a role for this kinase in angiogenesis in the labyrinthine region of the placenta , 1999, Current Biology.
[153] N. Rosen,et al. V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[154] A. Jimeno,et al. Analysis of potential predictive factors of clinical benefit in patients (pts) with metastatic colorectal cancer (MCRC) treated with single-agent cetuximab as first-line treatment , 2007 .
[155] P. Hirth,et al. Preclinical development of a novel inhibitor of oncogenic B-Raf. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[156] H. Friess,et al. Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha. , 1992, The Journal of clinical investigation.
[157] John Calvin Reed,et al. Bcl-2 Targets the Protein Kinase Raf-1 to Mitochondria , 1996, Cell.
[158] Suk Woo Nam,et al. BRAF and KRAS mutations in stomach cancer , 2003, Oncogene.
[159] G. Baillie,et al. Chemoresistant KM12C colon cancer cells are addicted to low cyclic AMP levels in a phosphodiesterase 4-regulated compartment via effects on phosphoinositide 3-kinase. , 2007, Cancer research.
[160] J. Sato,et al. MAP kinases, phosphatidylinositol 3‐kinase, and p70 S6 kinase mediate the mitogenic response of human endothelial cells to vascular endothelial growth factor , 1999, Journal of cellular physiology.
[161] W. Kolch,et al. The Raf‐1 kinase associates with vimentin kinases and regulates the structure of vimentin filaments , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[162] S. Kasibhatla,et al. Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity. , 2007, Journal of medicinal chemistry.
[163] S. S. Koh,et al. Over-expression of c-raf-1 proto-oncogene in liver cirrhosis and hepatocellular carcinoma. , 2004, Hepatology research : the official journal of the Japan Society of Hepatology.
[164] W. Scheuer,et al. Combination Treatment with Erlotinib and Pertuzumab against Human Tumor Xenografts Is Superior to Monotherapy , 2005, Clinical Cancer Research.
[165] A. Adjei. The role of mitogen-activated ERK-kinase inhibitors in lung cancer therapy. , 2005, Clinical lung cancer.
[166] J. Hecht,et al. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[167] C. Cerni,et al. Cdc25A phosphatase suppresses apoptosis induced by serum deprivation , 2001, Oncogene.
[168] Doriano Fabbro,et al. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase , 1996, Nature Medicine.
[169] A. Dritschilo,et al. Combination with liposome-entrapped, ends-modified raf antisense oligonucleotide (LErafAON) improves the anti-tumor efficacies of cisplatin, epirubicin, mitoxantrone, docetaxel and gemcitabine , 2004, Anti-cancer drugs.
[170] L. Schwartz,et al. A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma , 2006, Investigational New Drugs.
[171] Silvia Benvenuti,et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. , 2007, Cancer research.
[172] Vivienne Marsh,et al. Biological Characterization of ARRY-142886 (AZD6244), a Potent, Highly Selective Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor , 2007, Clinical Cancer Research.
[173] C. Der,et al. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer , 2007, Oncogene.
[174] E. Eisenhauer,et al. Phase II randomized study of ISIS 3521 and ISIS 5132 in patients with locally advanced or metastatic colorectal cancer: a National Cancer Institute of Canada clinical trials group study. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[175] Sourav Bandyopadhyay,et al. Systematic identification of functional orthologs based on protein network comparison. , 2006, Genome research.
[176] Dagmara Rusinek,et al. [BRAF initiating mutations in the papillary thyroid carcinoma]. , 2006, Endokrynologia Polska.
[177] I. Ahmad,et al. Systemic delivery of RafsiRNA using cationic cardiolipin liposomes silences Raf-1 expression and inhibits tumor growth in xenograft model of human prostate cancer. , 2005, International journal of oncology.
[178] P. Wipf,et al. The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non–small cell lung cancer xenografts , 2005, Molecular Cancer Therapeutics.
[179] P. Lyne,et al. Linking molecular characteristics to the pharmacological response of a panel of cancer cell lines to the BRAF inhibitor, AZ628 , 2007 .
[180] K. Chayama,et al. Clinicopathologic and genetic characteristics of gastric cancer in young male and female patients. , 2006, Oncology reports.
[181] A. Dritschilo,et al. Pharmacokinetics, toxicity, and efficacy of ends-modified raf antisense oligodeoxyribonucleotide encapsulated in a novel cationic liposome. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[182] H. Namba,et al. Different structural components of conventional papillary thyroid carcinoma display mostly identical BRAF status , 2007, International journal of cancer.
[183] T. Whiteside,et al. Correlation of constitutive activation of raf‐1 with morphological transformation and abrogation of tyrosine phosphorylation of distinct sets of proteins in human squamous carcinoma cells , 1997, Molecular carcinogenesis.
[184] P. M. Campbell,et al. K-Ras promotes growth transformation and invasion of immortalized human pancreatic cells by Raf and phosphatidylinositol 3-kinase signaling. , 2007, Cancer research.
[185] Trey Ideker,et al. CellCircuits: a database of protein network models , 2006, Nucleic Acids Res..
[186] G. Parmigiani,et al. The Consensus Coding Sequences of Human Breast and Colorectal Cancers , 2006, Science.
[187] D. Cameron,et al. Raf-1 is the predominant Raf isoform that mediates growth factor-stimulated growth in ovarian cancer cells. , 2006, Carcinogenesis.
[188] K. Fransén,et al. Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. , 2003, Carcinogenesis.
[189] D. Tuveson,et al. Suppression of BRAF(V599E) in human melanoma abrogates transformation. , 2003, Cancer research.
[190] G. Linette,et al. Randomized phase II study of dacarbazine with or without sorafenib in patients with advanced melanoma , 2007 .
[191] I. Judson,et al. HDAC Inhibitors and Cardiac Safety , 2007, Clinical Cancer Research.
[192] Xiaosong Zhang,et al. Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy , 2007, British Journal of Cancer.
[193] W. Min,et al. Chemoresistance of endothelial cells induced by basic fibroblast growth factor depends on Raf-1-mediated inhibition of the proapoptotic kinase, ASK1. , 2007, Cancer research.
[194] M. Omary,et al. Raf-1 activation disrupts its binding to keratins during cell stress , 2004, The Journal of cell biology.
[195] B. Burtness. Her signaling in pancreatic cancer , 2007, Expert opinion on biological therapy.
[196] W. Kolch. Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. , 2000, The Biochemical journal.
[197] S H Lee,et al. BRAF mutations in non-Hodgkin's lymphoma , 2003, British Journal of Cancer.
[198] L. Jardines,et al. Activation of Raf-1 in human pancreatic adenocarcinoma. , 1997, The Journal of surgical research.
[199] M. Marra,et al. Targeting Raf-kinase: molecular rationales and translational issues. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[200] B. Sander,et al. Mutations in the BRAF and N-ras genes in childhood acute lymphoblastic leukaemia , 2005, Leukemia.
[201] O. Sheils,et al. BRAF T1799A Mutation Occurring in a Case of Malignant Struma Ovarii , 2007, International journal of surgical pathology.
[202] Toshikazu Ebisuzaki,et al. Nuclear magnetic resonance and molecular dynamics studies on the interactions of the Ras-binding domain of Raf-1 with wild-type and mutant Ras proteins. , 1999, Journal of molecular biology.
[203] C. Rudin,et al. Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[204] Y. Miyata,et al. Hsp90 inhibitor geldanamycin and its derivatives as novel cancer chemotherapeutic agents. , 2005, Current pharmaceutical design.
[205] M. Xing,et al. BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells. , 2007, The Journal of clinical endocrinology and metabolism.
[206] T. Ideker,et al. Modeling cellular machinery through biological network comparison , 2006, Nature Biotechnology.
[207] C. Rudin,et al. Delivery of a Liposomal c-raf-1 Antisense Oligonucleotide by Weekly Bolus Dosing in Patients with Advanced Solid Tumors , 2004, Clinical Cancer Research.
[208] M. Moasser. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis , 2007, Oncogene.
[209] M. Marra,et al. The farnesyltransferase inhibitor R115777 (ZARNESTRA®) enhances the pro-apoptotic activity of interferon-α through the inhibition of multiple survival pathways (International Journal of Cancer (2007) 121, (2317-2330)) , 2008 .
[210] A. Flanagan,et al. In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low‐grade serous tumours , 2004, The Journal of pathology.
[211] Herb Chen,et al. ZM336372, a Raf-1 activator, inhibits growth of pheochromocytoma cells. , 2006, The Journal of surgical research.
[212] L. Fecher,et al. Toward a molecular classification of melanoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[213] R. Reis,et al. Mutation analysis of B-RAF gene in human gliomas , 2005, Acta Neuropathologica.
[214] M. Feldman,et al. Inhibition of tumor endothelial ERK activation, angiogenesis, and tumor growth by sorafenib (BAY43-9006). , 2006, The American journal of pathology.
[215] Vicki Betts,et al. Disruption of the Rb-Raf-1 Interaction Inhibits Tumor Growth and Angiogenesis , 2004, Molecular and Cellular Biology.
[216] M. Ostland,et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.